Announcements Trials
Browse Landscape

Phase

Phase 2/3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Lung Neoplasms 12Ovarian Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Carcinoma, Renal Cell 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Glioblastoma 3Endometrial Neoplasms 3Cholangiocarcinoma 3Breast Neoplasms 3Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Nasopharyngeal Carcinoma 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Lymphoid Interstitial Pneumonia 2Liposarcoma 2

Interventions

Magnetic Resonance Spectroscopy 10Specimen Handling 9Cisplatin 7Radiotherapy, Intensity-Modulated 6Platinum 61,2-diaminocyclohexaneplatinum II citrate 6pembrolizumab 5Cetuximab 5(225)Ac-DOTA-c(RGDyK) 4Carboplatin 3Biopsy 3ipatasertib 2X-Rays 2Taxes 2Radiotherapy 2Radiation 2Paclitaxel 2Interviews as Topic 2Immunoglobulin G 2Disulfides 2peposertib 1merphos 1durvalumab 1dehydroftorafur 1cabozantinib 1atezolizumab 1Tretinoin 1Surveys and Questionnaires 1Standard of Care 1Radiotherapy, Image-Guided 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hypopharyngeal Neoplasms × Immunoglobulin G × 90 days × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT03258554 2026-06-02

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

National Cancer Institute (NCI)

Phase 2/3 Completed
196 enrolled 31 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡